文献速递血栓与止血

抗癌治疗诱导动脉和静脉血栓形成的机制

Mechanisms of anticancer treatment-induced arterial and venous thrombosis.
PubMed 文献 · J Thromb Haemost · 2025-11-05

本叙述性综述聚焦实体瘤,探讨全身抗癌治疗相关血栓形成的发病机制,涵盖凝血激活、血管内皮损伤、死亡和濒死肿瘤细胞物质的促凝效应及炎症介质的作用,并指出当前对抗癌治疗相关免疫血栓形成机制认识不足,需更有效生物标志物指导血栓预防。

要点

  • 抗癌治疗相关血栓形成是显著临床问题,与较差预后相关。
  • 动脉事件虽较静脉血栓栓塞少见,但致残率高且常致命。
  • 抗癌治疗相关免疫血栓形成机制认识不足,需有效预测生物标志物。

核心结论

  • 更深入理解治疗相关癌症相关血栓形成的发病机制将有助于识别更有效的生物标志物以指导血栓预防。

研究设计与样本

  • 叙述性综述,聚焦实体瘤,探讨全身抗癌治疗血栓效应的发病机制。

主要发现

  • 抗癌治疗相关血栓形成机制包括凝血激活、血管内皮损伤、死亡和濒死肿瘤细胞物质的促凝效应及炎症介质的作用。
  • 尽管癌症相关血栓形成已被广泛研究,但癌症治疗引起血栓形成的具体机制仍知之甚少。
  • 与癌症治疗相关的免疫血栓形成发病机制尤其不明确。

局限性

  • 尽管癌症相关血栓形成已被广泛研究,但癌症治疗引起血栓形成的具体机制仍知之甚少。
  • 与癌症治疗相关的免疫血栓形成发病机制尤其不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent advances in cancer treatment have improved outcomes for patients across a wide variety of cancers. However, despite the introduction of more targeted therapies, including those that harness the body's natural immune system, cancer-associated thrombosis, particularly during therapy, is a significant clinical problem associated with poorer outcomes. Although venous thromboembolism is more common, arterial events cause significant morbidity and are frequently fatal. In addition to the well-established chemotherapeutic regimens, multiple therapies are now used in the first-line setting, including antibody-based treatments, immunotherapy, and hormone receptor modulators. Many cancers are now being managed as chronic diseases with long-term maintenance therapies in an increasingly older patient population with significant comorbidities. With this change in the treatment landscape, predictive biomarkers are needed to effectively identify patients and treatments associated with the highest risk of thrombosis in the current cancer population. Although cancer-associated thrombosis has been extensively studied, the specific mechanisms by which cancer therapy causes thrombosis remain poorly understood. The pathogenesis of immunothrombosis associated with cancer treatments in particular is poorly defined. Focusing on solid tumors, the aim of this narrative review is to explore our current understanding of the pathogenesis of thrombotic effects of systemic cancer treatment. These include coagulation activation, vascular endothelial damage, procoagulant effects of material from dead and dying tumor cells, as well as the role of inflammatory mediators. Greater understanding of pathogenesis of treatment-related cancer-associated thrombosis will lead to the identification of more effective biomarkers to guide thromboprophylaxis.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Albasanz-García P, Ward MP, Norris LA, et al. Mechanisms of anticancer treatment-induced arterial and venous thrombosis. J Thromb Haemost. 2025. PMID: 41203043. doi:10.1016/j.jtha.2025.10.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。